A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units to detect instances of atrial fibrillation.
The technology, called electrocardiomatrix, goes further than standard cardiac telemetry by examining large amounts of telemetry data in a way that’s so detailed it’s impractical for individual clinicians to attempt.
Co-inventor Jimo Borjigin, Ph.D., recently published the latest results from her electrocardiomatrix technology in Stroke. Among stroke patients with usable data (260 of 265), electrocardiomatrix was highly accurate in identifying those with Afib.
“We validated the use of our technology in a clinical setting, finding the electrocardiomatrix was an accurate method to determine whether a stroke survivor had an Afib,” says Borjigin, an associate professor of neurology and molecular and integrative physiology at Michigan Medicine.
A crucial metric
After a stroke, neurologists are tasked with identifying which risk factors may have contributed in order to do everything possible to prevent another event.
That makes detecting irregular heartbeat an urgent concern for these patients, explains first author Devin Brown, M.D., professor of neurology and a stroke neurologist at Michigan Medicine.
“Atrial fibrillation is a very important and modifiable risk factor for stroke,” Brown says.
Importantly, the electrocardiomatrix identification method was highly accurate for the 212 patients who did not have a history of Afib, Borjigin says. She says this group is most clinically relevant, because of the importance of determining whether stroke patients have previously undetected Afib.
When a patient has Afib, their irregular heartbeat can lead to blood collecting in their heart, which can form a stroke-causing clot. Many different blood thinners are on the market today, making it easier for clinicians to get their patients on an anticoagulant they’ll take as directed.
The most important part is determining Afib’s presence in the first place.
Brown says challenges persist in detecting intermittent Afib during stroke hospitalization.
“More accurate identification of Afib should translate into more strokes prevented,” she says.
Once hospitalized in the stroke unit, patients are typically placed on continuous heart rhythm monitoring. Stroke neurologists want to detect possible intermittent Afib that initial monitoring like an electrocardiogram, or ECG, would have missed.
Because a physician can’t reasonably review every single heartbeat, current monitoring technology flags heart rates that are too high, Brown says. The neurologist then reviews these flagged events, which researchers say could lead to some missed Afib occurrences, or false positives in patients with different heart rhythm issues.
In contrast, Borjigin’s electrocardiomatrix converts two-dimensional signals from the ECG into a three-dimensional heatmap that allows for rapid inspection of all collected heartbeats. Borjigin says this method permits fast, accurate and intuitive detection of cardiac arrhythmias. It also minimizes false positive as well as false negative detection of arrhythmias.
“We originally noted five false positives and five false negatives in the study,” Borjigin says, “but expert review actually found the electrocardiomatrix was correct instead of the clinical documentation we were comparing it to.”
The Borjigin lab also recently demonstrated the usefulness of the electrocardiomatrix to differentiate between Afib and atrial flutter. In addition, the lab has shown the ability of electrocardiomatrix to capture reduced heart-rate variability in critical care patients.
Borjigin says she envisions electrocardiomatrix technology will one day be used to assist the detection of all cardiac arrhythmias online or offline and side-by-side with the use of ECG.
“I believe that sooner or later, electrocardiomatrix will be used in clinical practice to benefit patients,” she says.
Disclosure: Borjigin is the co-inventor of electrocardiomatrix, for which she holds a patent in Japan (6348226); and for which the Regents of the University of Michigan hold the patent in the United States (9918651).
Source: Read Full Article